So the valuation is based on discussions with management - valuation has dropped after discussions with management - so what are management not telling us - so so so flamin silent!!!!.
Don't like this bit: "Our valuation includes a consideration of the company's three other products, namely; Estradiol MDTS (U.S.) or Evamist, Recuvyra, and Estradiol MDTS (ex-U.S.) which are marketed respectively under licence by KV Pharmaceuticals, Eli Lilly, and Gedeon Richter. On a combined basis, the contribution of these three products to our new fair value is negligible".
And what about this bit about the new "projects": "We have not at this stage attributed any value to two pre-clinical stage novel therapeutic candidates flagged, but as yet not detailed, by management". Still not detailed by management and it was trotted out last August that they were going to do something and confirmed in November with updates supposedly in Q4 2013 or Q1 2014. Well this is going to be interesting isn't it!!??.
At this stage I can't see value for money in the excruciatingly high salaries. all IMO so DYOR.
"We do not consider Acrux to have a moat...." - I think head office does though with the drawbridge up!! :-)
"Acrux is a medical research and development company" - hopefully still is.
"Risks relate to the staged development of new products leveraging its proprietary drug-delivery technology, regulatory decisions, poor execution by marketing or out-licensing partners, success of competitor products, and general funding challenges" - phew they didn't mention management.
All IMO so DYOR.
ACR Price at posting:
$1.91 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)